Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16360450rdf:typepubmed:Citationlld:pubmed
pubmed-article:16360450lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C0059865lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:16360450lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:16360450pubmed:issue6lld:pubmed
pubmed-article:16360450pubmed:dateCreated2005-12-19lld:pubmed
pubmed-article:16360450pubmed:abstractTextTo investigate the effects of the selective cyclooxygenase-2 (COX-2) inhibitor etodolac on prostate cancer cell lines in vitro and in vivo and on E-cadherin expression in prostate cancer cells.lld:pubmed
pubmed-article:16360450pubmed:languageenglld:pubmed
pubmed-article:16360450pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16360450pubmed:citationSubsetIMlld:pubmed
pubmed-article:16360450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16360450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16360450pubmed:statusMEDLINElld:pubmed
pubmed-article:16360450pubmed:monthDeclld:pubmed
pubmed-article:16360450pubmed:issn1527-9995lld:pubmed
pubmed-article:16360450pubmed:authorpubmed-author:ShirakawaTosh...lld:pubmed
pubmed-article:16360450pubmed:authorpubmed-author:FujisawaMasat...lld:pubmed
pubmed-article:16360450pubmed:authorpubmed-author:KamidonoSadao...lld:pubmed
pubmed-article:16360450pubmed:authorpubmed-author:GotohAkinobuAlld:pubmed
pubmed-article:16360450pubmed:authorpubmed-author:WadaYoshitaka...lld:pubmed
pubmed-article:16360450pubmed:authorpubmed-author:ShigemuraKats...lld:pubmed
pubmed-article:16360450pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16360450pubmed:volume66lld:pubmed
pubmed-article:16360450pubmed:ownerNLMlld:pubmed
pubmed-article:16360450pubmed:authorsCompleteYlld:pubmed
pubmed-article:16360450pubmed:pagination1239-44lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:meshHeadingpubmed-meshheading:16360450...lld:pubmed
pubmed-article:16360450pubmed:year2005lld:pubmed
pubmed-article:16360450pubmed:articleTitleAntitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo.lld:pubmed
pubmed-article:16360450pubmed:affiliationDivision of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.lld:pubmed
pubmed-article:16360450pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16360450lld:pubmed